Consun Pharmaceutical Group Limited (01681.HK) disclosed that its total issued share capital stood at 847,973,407 shares as of 21 October 2025, unchanged from the opening balance on 20 October 2025.

According to the disclosure, several share repurchases for cancellation were conducted between 14 and 21 October 2025 but remained uncancelled as of 21 October 2025. The total number of shares involved in these repurchases was 1,306,000. Individual transactions included repurchases on 14, 15, 16, 17, 20, and 21 October 2025, with repurchase prices varying between HKD 15.076 and HKD 15.7565 per share.

Additionally, on 21 October 2025, a separate on-market repurchase of 269,000 shares was executed at a highest price of HKD 15.6 and a lowest price of HKD 15.44, totaling HKD 4,169,950. The company remains authorised to repurchase up to 85,126,334 shares as per the resolution dated 22 May 2025, with a cumulative 6,501,000 shares repurchased so far, representing approximately 7.6369% of its issued shares at the time of the resolution. A moratorium is in place until 20 November 2025 for any new share issuance or transfer of treasury shares under the applicable rules.